American Journal on Addictions最新文献_第3页

AAAP conference agenda

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-03-08 DOI: 10.1111/ajad.70017

引用次数: 0

Medical Update

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-03-08 DOI: 10.1111/ajad.70005

引用次数: 0

Film & Media Workshop

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-03-08 DOI: 10.1111/ajad.70006

引用次数: 0

Save the Date - Annual Meeting 2025

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-03-08 DOI: 10.1111/ajad.70022

引用次数: 0

Proceedings of the 35th Annual Meeting & Scientific Symposium

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-03-08 DOI: 10.1111/ajad.70018

Thomas R. Kosten MD, Coreen B. Domingo DrPH, MSW

引用次数: 0

Cannabis involvement in posttraumatic stress disorder emergency department visits after cannabis legalization.

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-03-02 DOI: 10.1111/ajad.70014

Laurent Perrault-Sequeira, Michael Pugliese, Rachael MacDonald-Spracklin, Jennifer Xiao, Stephen McCarthy, Daniel T Myran

{"title":"Cannabis involvement in posttraumatic stress disorder emergency department visits after cannabis legalization.","authors":"Laurent Perrault-Sequeira, Michael Pugliese, Rachael MacDonald-Spracklin, Jennifer Xiao, Stephen McCarthy, Daniel T Myran","doi":"10.1111/ajad.70014","DOIUrl":"https://doi.org/10.1111/ajad.70014","url":null,"abstract":"Background and objectives: Individuals with posttraumatic stress disorder (PTSD) have an elevated risk of cannabis use disorder. However, the effect of cannabis legalization on use among individuals with PTSD is unclear. We evaluated changes in cannabis involvement in emergency department (ED) visits for PTSD after medical and nonmedical legalization in Ontario, Canada.Methods: This repeated cross-sectional study used health administrative data to identify all ED visits for PTSD among Ontario residents aged 10-105 between 2008 and 2022 (n = 15.7 million). We identified PTSD ED visits with a co-diagnosis of cannabis (main exposure) or alcohol (control condition) and examined changes across four policy periods (medical legalization with restrictions, expanded medical legalization, nonmedical legalization with restrictions, and nonmedical commercial expansion) using Poisson models.Results: Among 381,450 PTSD ED visits, 4593 (1.29%) co-involved cannabis and 11,625 (3.05%) co-involved alcohol. Rates of cannabis involvement in PTSD ED visits increased by 151% (Incidence Rate Ratio [IRR]: 2.51; 95% CI: 2.24, 2.82) between the first and last policy periods (0.13 vs. 0.33 per 100,000 individuals), while alcohol-involvement increased by 58% (IRR: 1.58; 95% CI: 1.47, 1.68). Cannabis involvement in PTSD ED visits increased steadily over the study period, with no significant association between policy periods and this trend.Discussion and conclusions: Cannabis involvement in PTSD ED visits has increased over time during a period of liberalization of cannabis policy, but may be attributed to increased access and normalization rather than policy changes directly.Scientific significance: Findings underscore the need for improved detection of and targeted interventions for disordered cannabis use among individuals with PTSD in regions with legalized cannabis.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder.

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-02-28 DOI: 10.1111/ajad.70015

Helen E Bird, William A Clarke, Craig W Hendrix, Kelly E Dunn, Andrew S Huhn

引用次数: 0

The 24-year course of substance use disorders in patients with borderline personality disorder and personality-disordered comparison subjects.

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-02-25 DOI: 10.1111/ajad.70012

Mary C Zanarini, Christina M Temes, Isabel V Glass, Frances R Frankenburg, Garrett M Fitzmaurice, Brandon T Unruh, Roger D Weiss

{"title":"The 24-year course of substance use disorders in patients with borderline personality disorder and personality-disordered comparison subjects.","authors":"Mary C Zanarini, Christina M Temes, Isabel V Glass, Frances R Frankenburg, Garrett M Fitzmaurice, Brandon T Unruh, Roger D Weiss","doi":"10.1111/ajad.70012","DOIUrl":"https://doi.org/10.1111/ajad.70012","url":null,"abstract":"Background and objectives: The purpose of this study is to detail the long-term course of substance use disorders (SUDs) among patients with borderline personality disorder (BPD) and subjects with other personality disorders (OPD).Methods: Two hundred and ninety patients with BPD and 72 subjects with OPD were assessed at baseline and 12 contiguous waves of follow-up as part of the McLean Study of Adult Development (MSAD). The SCID-I for DSM-III-R Axis I disorders was administered 13 times (at baseline admission and at 12 follow-up periods). Kaplan-Meier analyses were used to assess time-to-remission (2-12 years in length), time-to-recurrence (2-12 years after first remission), and cumulative time-to-new onsets of alcohol and drug use disorders.Results: Both study groups achieved high rates of remission (ranging from 12-year long to 2-year long) from alcohol use disorder (AUD) (BPD: 64%-91%; OPD: 80%-100%) and drug use disorder (DUD) (BPD: 71%-100%; OPD: 75%-100%). Recurrences (following 12-year long and 2-year long remissions) of AUD (BPD: 24%-63%; OPD: 46%-70%) and DUD (BPD: 28%-67%; OPD: 0%-38%) were not uncommon. Cumulative rates of new onsets during the 24 years of prospective follow-up of AUD (BPD: 5%-27%; OPD: 2%-10%) and DUD (BPD: 5%-21%; OPD: 7%-18%) were less common.Discussion and conclusions: Remissions of alcohol and drug use disorders among borderline patients are very common but recurrences are not uncommon. Results also suggest that new onsets of these disorders are relatively rare.Scientific significance: The course of SUDs in those with BPD is more complex than found in prior shorter-term studies.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case series: Symptom-inhibited fentanyl induction (SIFI) onto treatment-dose opioid agonist therapy in a community setting.

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-02-18 DOI: 10.1111/ajad.70011

Pouya Azar, Jane J Kim, Ruth Davison, Zoran Barazanci, Martha J Ignaszewski, James S H Wong, Jessica Machado, Marianne Harris, Michael Krausz, Nickie Mathew, Andrew Herring, Julio S G Montaner

{"title":"Case series: Symptom-inhibited fentanyl induction (SIFI) onto treatment-dose opioid agonist therapy in a community setting.","authors":"Pouya Azar, Jane J Kim, Ruth Davison, Zoran Barazanci, Martha J Ignaszewski, James S H Wong, Jessica Machado, Marianne Harris, Michael Krausz, Nickie Mathew, Andrew Herring, Julio S G Montaner","doi":"10.1111/ajad.70011","DOIUrl":"https://doi.org/10.1111/ajad.70011","url":null,"abstract":"Background and objectives: Existing opioid agonist therapy (OAT) guidelines are far from sufficient to address rising opioid tolerances and potency of the unregulated opioid market in North America. Inadequate starting doses of OAT are a universally recognized barrier for people who use fentanyl. Our objectives are to present a novel induction protocol called symptom-inhibiting fentanyl induction (SIFI) that uses rapid intravenous fentanyl administration to inhibit symptoms of opioid withdrawal.Methods: We describe two cases highlighting the potential clinical utility of SIFI.Results: This case series demonstrates two safe and successful transitions onto higher-than-standard doses of methadone and slow-release oral morphine harnessing an emerging approach of SIFI in a community clinic setting.Discussion and conclusions: These results support emerging evidence that SIFI is safe and feasible to meet patients' opioid requirements and facilitate rotation onto OAT. Further studies are needed to increase the generalizability of these findings.Scientific significance: Safe transitions onto treatment-dose OAT are of heightened clinical importance at a time when fentanyl and high-potency synthetic opioids are now the norm. SIFI is a novel induction method that could address significant gaps in the currently available OAT options in the fentanyl era.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe gamma-hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series.

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-02-14 DOI: 10.1111/ajad.70013

Cara M Borelli, Newman Kessler, Daniel Suter, Annie Levesque

{"title":"Severe gamma-hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series.","authors":"Cara M Borelli, Newman Kessler, Daniel Suter, Annie Levesque","doi":"10.1111/ajad.70013","DOIUrl":"https://doi.org/10.1111/ajad.70013","url":null,"abstract":"Background and objectives: Gamma-hydroxybutyrate (GHB) use is clinically important in both the settings of overdose and withdrawal. GHB withdrawal varies in severity, and although mild cases can be managed outpatient, there are a range of presentations that include progression to severe withdrawal that require inpatient hospitalization.Methods: We report a case series of two patients with severe GHB withdrawal who experienced complications of delirium, hemodynamic lability, and rhabdomyolysis and describe the treatment of these two cases of complex withdrawal.Results: The first patient was successfully treated with a combination of a benzodiazepine taper and symptom-triggered benzodiazepines with baclofen as an adjunct. The second patient had more severe symptoms and required intubation with a midazolam infusion, dexmedetomidine infusion, phenobarbital, baclofen, and a combination of a benzodiazepine taper and symptom-triggered benzodiazepines.Discussion and conclusions: This case series highlights the potential complications of GHB withdrawal including delirium, hemodynamic lability, and rhabdomyolysis. Although rare in the United States, those working in addiction should have familiarity with the clinical course and complications of severe GHB withdrawal.Scientific significance: As one of the few detailed reports on severe GHB withdrawal and its potential complications, our findings extend the current body of literature by detailing the successful application of a multi-modal treatment of severe GHB withdrawal.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0